Study Spotlights Rising Use, Spending on Asthma Biologics
April
23
A recently released study from Prime Therapeutics LLC highlights an eyebrow-raising trend: Over the last two and a half years, the number of the PBM’s commercially insured members with asthma who used biologic medicines nearly doubled, and so did spending on those drugs.
Prime, which is owned by 18 Blue Cross and Blue Shield plans, examined integrated pharmacy and medical claims from 14 million commercially insured members from January 2017 to June 2019. It found that the number of members with an asthma diagnosis using one of five asthma biologics — Cinqair (reslizumab), Dupixent (dupilumab), Fasenra (benralizumab), Nucala (mepolizumab) and Xolair (omalizumab) — increased by 78%, from 3.3 users per 10,000 members to 5.8 out of 10,000.
© 2023 MMIT
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile